三联疗法-话题@MedSci

#三联疗法#

56篇内容 | 2209人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1613726, encodeId=d20a1613e267a, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Nature子刊：禁食+维生素C+化疗的三联疗法对难治疗的癌症有效, objectType=article, longId=194147, objectId=534919414e6c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=534919414e6c, replyNumber=0, likeNumber=90, createdTime=2020-05-16, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=534919414e6c, moduleTitle=Nature子刊：禁食+维生素C+化疗的三联疗法对难治疗的癌症有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=534919414e6c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613725, encodeId=3d611613e25eb, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=欧洲药品管理局：支持诺华的Enerzair Breezhaler三联疗法治疗不受控制的哮喘, objectType=article, longId=193381, objectId=964219338183, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=964219338183, replyNumber=0, likeNumber=59, createdTime=2020-05-04, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=964219338183, moduleTitle=欧洲药品管理局：支持诺华的Enerzair Breezhaler三联疗法治疗不受控制的哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=964219338183)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613724, encodeId=d7a61613e24a3, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=美国FDA批准三联疗法Trijardy™XR治疗2型糖尿病, objectType=article, longId=186951, objectId=648b186951e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=648b186951e9, replyNumber=0, likeNumber=77, createdTime=2020-01-31, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=648b186951e9, moduleTitle=美国FDA批准三联疗法Trijardy™XR治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=648b186951e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613723, encodeId=57331613e23e7, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势, objectType=article, longId=186743, objectId=96bb186e4389, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96bb186e4389, replyNumber=0, likeNumber=54, createdTime=2020-01-27, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96bb186e4389, moduleTitle=晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=96bb186e4389)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613722, encodeId=2d2c1613e2214, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Semin Arthritis Rheu：类风湿性关节炎中性粒细胞-淋巴细胞比率及其预测三联疗法失败的能力, objectType=article, longId=185923, objectId=73c11859238f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73c11859238f, replyNumber=0, likeNumber=60, createdTime=2020-01-10, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73c11859238f, moduleTitle=Semin Arthritis Rheu：类风湿性关节炎中性粒细胞-淋巴细胞比率及其预测三联疗法失败的能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73c11859238f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613721, encodeId=a0b71613e2165, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=PNAS：“三联疗法”实现肿瘤高效率杀伤, objectType=article, longId=185803, objectId=57d9185803a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57d9185803a5, replyNumber=0, likeNumber=74, createdTime=2020-01-08, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57d9185803a5, moduleTitle=PNAS：“三联疗法”实现肿瘤高效率杀伤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=57d9185803a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613720, encodeId=7bde1613e2086, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Clinical Gastroenterology H：铋剂与标准三联疗法的结合可消除90％以上患者的幽门螺杆菌感染, objectType=article, longId=185377, objectId=ac2b1853e7d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac2b1853e7d6, replyNumber=0, likeNumber=39, createdTime=2019-12-29, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac2b1853e7d6, moduleTitle=Clinical Gastroenterology H：铋剂与标准三联疗法的结合可消除90％以上患者的幽门螺杆菌感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac2b1853e7d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613719, encodeId=893b1613e19dd, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=阿斯利康的三联疗法PT010在中国获批用于COPD患者, objectType=article, longId=185187, objectId=f96418518e00, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f96418518e00, replyNumber=0, likeNumber=80, createdTime=2019-12-26, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f96418518e00, moduleTitle=阿斯利康的三联疗法PT010在中国获批用于COPD患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f96418518e00)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613718, encodeId=1b3b1613e18f8, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=THER ADV GASTROENTER：右兰索拉唑为基础的三联疗法可以根治幽门螺杆菌感染, objectType=article, longId=184841, objectId=e12c184841e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e12c184841e5, replyNumber=0, likeNumber=61, createdTime=2019-12-18, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e12c184841e5, moduleTitle=THER ADV GASTROENTER：右兰索拉唑为基础的三联疗法可以根治幽门螺杆菌感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e12c184841e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613717, encodeId=c63e1613e1790, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Chiesi Group宣布其单吸入器三联疗法治疗严重哮喘的两项III期阳性数据, objectType=article, longId=181536, objectId=e56f1815365e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e56f1815365e, replyNumber=0, likeNumber=66, createdTime=2019-10-20, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e56f1815365e, moduleTitle=Chiesi Group宣布其单吸入器三联疗法治疗严重哮喘的两项III期阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e56f1815365e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613716, encodeId=a4de1613e162d, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Lancet：单次吸入三联疗法治疗无法控制的哮喘, objectType=article, longId=180411, objectId=580418041173, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=580418041173, replyNumber=0, likeNumber=73, createdTime=2019-10-04, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=580418041173, moduleTitle=Lancet：单次吸入三联疗法治疗无法控制的哮喘, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=580418041173)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613715, encodeId=0e151613e15e0, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=阿斯利康的三联疗法Breztri Aerosphere治疗晚期COPD达到了主要终点, objectType=article, longId=178351, objectId=9a9a1e83512e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a9a1e83512e, replyNumber=0, likeNumber=65, createdTime=2019-08-30, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a9a1e83512e, moduleTitle=阿斯利康的三联疗法Breztri Aerosphere治疗晚期COPD达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9a1e83512e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613714, encodeId=2f8b1613e145a, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=BMJ：四联抗HIV疗法的疗效不优于三联疗法, objectType=article, longId=175094, objectId=3a0c1e50949c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a0c1e50949c, replyNumber=0, likeNumber=77, createdTime=2019-07-11, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a0c1e50949c, moduleTitle=BMJ：四联抗HIV疗法的疗效不优于三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a0c1e50949c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613713, encodeId=fdc81613e1307, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Eur Respir J：轻中度COPD用三联疗法用大炮打蚊子？, objectType=article, longId=158951, objectId=b4de15895199, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4de15895199, replyNumber=0, likeNumber=51, createdTime=2019-01-28, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4de15895199, moduleTitle=Eur Respir J：轻中度COPD用三联疗法用大炮打蚊子？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4de15895199)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613712, encodeId=12e61613e1251, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点, objectType=article, longId=154586, objectId=9b231545869e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b231545869e, replyNumber=0, likeNumber=66, createdTime=2018-11-30, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b231545869e, moduleTitle=Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b231545869e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613711, encodeId=48ef1613e11b3, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=BMJ：慢性阻塞性肺病的三联疗法, objectType=article, longId=153043, objectId=82bd153043e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82bd153043e3, replyNumber=0, likeNumber=52, createdTime=2018-11-10, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82bd153043e3, moduleTitle=BMJ：慢性阻塞性肺病的三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82bd153043e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613710, encodeId=caa91613e10ef, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=标准三联疗法与左氧氟沙星替代疗法治疗幽门螺杆菌感染的疗效比较, objectType=article, longId=151759, objectId=3cd2151e59d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3cd2151e59d6, replyNumber=0, likeNumber=78, createdTime=2018-10-25, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3cd2151e59d6, moduleTitle=标准三联疗法与左氧氟沙星替代疗法治疗幽门螺杆菌感染的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3cd2151e59d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613709, encodeId=782f1613e097b, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Circulation：三联疗法增加PCI后房颤患者的出血风险全新抗血栓建议怎么说？, objectType=article, longId=147928, objectId=914414e928c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=914414e928c7, replyNumber=0, likeNumber=79, createdTime=2018-09-02, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=914414e928c7, moduleTitle=Circulation：三联疗法增加PCI后房颤患者的出血风险全新抗血栓建议怎么说？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=914414e928c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613708, encodeId=c83a1613e08e0, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=Rheumatology：三联疗法：灾难性抗磷脂综合征患者的福音, objectType=article, longId=145310, objectId=c93614531082, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c93614531082, replyNumber=0, likeNumber=88, createdTime=2018-07-29, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c93614531082, moduleTitle=Rheumatology：三联疗法：灾难性抗磷脂综合征患者的福音, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c93614531082)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1613707, encodeId=ad961613e071a, content=<a href='/topic/show?id=a59419e9059' target=_blank style='color:#2F92EE;'>#三联疗法#</a>, objectTitle=JAMA：老年人浸润性膀胱癌行根治性手术与三联疗法后生存结果与费用的差异比较, objectType=article, longId=142651, objectId=649f14265156, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649f14265156, replyNumber=0, likeNumber=78, createdTime=2018-07-08, rootId=0, userName=12498636m55(暂无昵称), userId=552519418574, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649f14265156, moduleTitle=JAMA：老年人浸润性膀胱癌行根治性手术与三联疗法后生存结果与费用的差异比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649f14265156)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

三联疗法

2020-05-29

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Nature子刊：禁食+维生素C+化疗的三联疗法对难治疗的癌症有效

2020-05-16

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

欧洲药品管理局：支持诺华的Enerzair Breezhaler三联疗法治疗不受控制的哮喘

2020-05-04

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

美国FDA批准三联疗法Trijardy™XR治疗2型糖尿病

2020-01-31

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

晚期肝细胞癌：Cabozantinib、Nivolumab和Ipilimumab的三联疗法具有显著优势

2020-01-27

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Semin Arthritis Rheu：类风湿性关节炎中性粒细胞-淋巴细胞比率及其预测三联疗法失败的能力

2020-01-10

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

PNAS：“三联疗法”实现肿瘤高效率杀伤

2020-01-08

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Clinical Gastroenterology H：铋剂与标准三联疗法的结合可消除90％以上患者的幽门螺杆菌感染

2019-12-29

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

阿斯利康的三联疗法PT010在中国获批用于COPD患者

2019-12-26

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

THER ADV GASTROENTER：右兰索拉唑为基础的三联疗法可以根治幽门螺杆菌感染

2019-12-18

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Chiesi Group宣布其单吸入器三联疗法治疗严重哮喘的两项III期阳性数据

2019-10-20

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Lancet：单次吸入三联疗法治疗无法控制的哮喘

2019-10-04

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

阿斯利康的三联疗法Breztri Aerosphere治疗晚期COPD达到了主要终点

2019-08-30

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

BMJ：四联抗HIV疗法的疗效不优于三联疗法

2019-07-11

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Eur Respir J：轻中度COPD用三联疗法用大炮打蚊子？

2019-01-28

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点

2018-11-30

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

BMJ：慢性阻塞性肺病的三联疗法

2018-11-10

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

标准三联疗法与左氧氟沙星替代疗法治疗幽门螺杆菌感染的疗效比较

2018-10-25

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Circulation：三联疗法增加PCI后房颤患者的出血风险全新抗血栓建议怎么说？

2018-09-02

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

Rheumatology：三联疗法：灾难性抗磷脂综合征患者的福音

2018-07-29

12498636m55(暂无昵称) (审核中...)

前往app查看评论内容

#三联疗法#

JAMA：老年人浸润性膀胱癌行根治性手术与三联疗法后生存结果与费用的差异比较

2018-07-08

科室
- - 订阅+
  - 更多科室
工具
服务